Microbleed prevalence and burden in anticoagulant-associated intracerebral bleed. 

 -  2019 
<br/><br/> Copyright (c) 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.  Prior studies suggest an association between Vitamin K antagonists (VKA) and cerebral microbleeds (CMBs); less is known about nonvitamin K oral anticoagulants (NOACs). In this observational study we describe CMB profiles in a multicenter cohort of 89 anticoagulation-related intracerebral hemorrhage (ICH) patients. CMB prevalence was 51% (52% in VKA-ICH, 48% in NOAC-ICH). NOAC-ICH patients had lower median CMB count [2(IQR:1-3) vs. 7(4-11); P < 0.001]; >=5 CMBs were less prevalent in NOAC-ICH (4% vs. 31%, P = 0.006). This inverse association between NOAC exposure and high CMB count persisted in multivariable logistic regression models adjusting for potential confounders (OR 0.10, 95%CI: 0.01-0.83; P = 0.034). 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>2328-9503 
<br/><br/><label>Standard No.: </label>10.1002/acn3.50834 [doi] PMC6689674 [pmc] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Anticoagulants/tu [Therapeutic Use]<br/>*Cerebral Hemorrhage/dt [Drug Therapy]<br/>*Vitamin K/tu [Therapeutic Use]<br/>Administration, Oral<br/>Aged<br/>Aged, 80 and over<br/>Cohort Studies<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Prevalence<br/>Retrospective Studies<br/>Stroke<br/>Vitamin K/ai [Antagonists & Inhibitors]
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Washington Hospital Center
<br/><br/><label>Index Terms--Occupation: </label><br/>Surgical Critical Care
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article